Other Clinical Trial - Second-line Treatment With Serplulimab, Lenvatinib,

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02426034` - A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer	Phase 4
	Not yet recruiting	`NCT04435652` - A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.	Phase 2/Phase 3

See also

Status

Clinical Trial

Phase

Completed

NCT02426034 - A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Phase 4

Not yet recruiting

NCT04435652 - A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Phase 2/Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05585580
Study type	Interventional
Source	Qilu Hospital of Shandong University
Contact	Lian Liu
Phone	0531-82169851
Email	tounao@126.com
Status	Recruiting
Phase	Phase 2
Start date	March 1, 2023
Completion date	March 1, 2025

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms